Hologic to showcase its comprehensive breast and skeletal health solutions portfolio at RSNA 2022

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX) will showcase its broad portfolio of breast and skeletal health products at the 108e Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from November 27 to December 1. Among the full line of breast biopsy and surgical solutions will be Hologic’s Affirm® The Contrast Biopsy software, which will be presented for the first time since its commercialization in the United States.

“As the global leader in breast imaging, we are committed to addressing the unmet needs of physicians and their patients across the continuum of breast care and look forward to engaging with industry leaders during of this year’s RSNA meeting to share our vision for the future of breast health,” said Erik Anderson, President of Hologic’s Breast and Skeletal Health Solutions Division. “We are also excited to introduce our new Affirm Contrast Biopsy technology, which is a great example of our commitment to physicians and patients in action.”

Affirm Contrast Biopsy software allows clinicians to target and acquire tissue samples in lesions identified with I-View® Contrast enhanced mammography software. The contrast solution offers healthcare facilities a viable and attractive alternative to breast MRI, which has historically been used to find and biopsy more elusive lesions, such as those that cannot be seen by mammography or ultrasound. While breast MRI can be time-consuming and expensive, contrast technology offers radiologists another option in the mammography suite that fills these gaps.1.2 In a recent clinical study, 98% of patients had an overall positive opinion of their procedural experience with Affirm Contrast Biopsy software.3

RSNA attendees can experience Hologic’s portfolio at Booth 1911 in South Hall Level 3 at McCormick Place in Chicago. In addition to the Affirmation Biopsy contrast software, Hologic will present its dimensions® mammography portfolio and Supersonic® MACH™ ultrasound systems.

Hologic will also host a series of CME and non-CME accredited medical education symposia and learning opportunities available to onsite and remote attendees. Medical education sessions include:

  • “Vertical biopsy with the Brevera® breast biopsy system: real-time imaging, verification and automated handling”

    Sunday, November 27: 11:45 a.m. – 12:45 p.m. CST

    Dr. Krystal Airola will demonstrate new vertical breast biopsy technologies that will improve accuracy, workflow, and patient experience. She will share her experiences with the Affirm 2D/3D Vertical Biopsy, Side Arm Approach, and the Brevera Breast Biopsy System, which integrates tissue acquisition, real-time imaging and verification, and manipulation of post-biopsy samples. Dr. Airola will also share cases and explain how to dramatically reduce patient time and discomfort in the biopsy room while maximizing biopsy room efficiency and clinical decision making.
  • “Emerging Ultrasound Technology in Liver Monitoring”

    Monday, November 28: 12:00 p.m. – 1:00 p.m. CST

    Learn more about advances in ultrasound technology with ShearWave™ Elastography. There are many opportunities to improve workflow efficiency in liver monitoring, which improves patient experience and outcomes. In this lecture, participants will review comparisons with existing and emerging ultrasound technologies and techniques.
  • “Current AI applications in mammography: Focus on Genius AI™ detection software”

    Tuesday, November 29: 12:00 p.m. – 1:00 p.m. CST

    Attendees will hear from an expert about the benefits of artificial intelligence (AI) in mammography screening. With the implementation of new high-resolution technologies, learn how AI can reduce dose, file sizes, and playback times. The focus will be on deep learning AI and the benefits of Genius AI Detection software in clinical decision making and increasing productivity.
  • “Round table: localization options”

    Wednesday, November 30: 12:00 p.m. – 1:00 p.m. CST

    Join a cross-disciplinary conversation about localization. Hear insights from leading radiologists and breast surgeons on what they like, what they use and why. What is the role of sons? What other technologies are available? What are the strengths and weaknesses of the different options?

About Hologic, Inc.

Hologic, Inc. is a global medical technology innovator focused primarily on improving the health and well-being of women through early detection and treatment. His advances include inventing the world’s first commercial 3D mammography™ system to fight breast cancer; leadership in screening for cervical cancer, sexually transmitted infections, respiratory diseases and the virus that causes COVID-19; and minimally invasive surgical technologies for uterine fibroids and abnormal uterine bleeding.

The company also advocates for women through the Hologic Global Women’s Health Index, which provides a roadmap of science-based data to improve women’s well-being, and Project Health Equality, which improves awareness, knowledge of research and access to quality care for underserved women. hologic.com

Hologic, 3D Mammography, 3Dimensions, Affirm, Brevera, Dimensions, Genius AI, I-View, Mach, Selenia, ShearWave, Supersonic and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc., and/ or its affiliates in the United States and/or other countries.

Forward-looking statements

This press release may contain forward-looking information that involves risks and uncertainties, including statements regarding the use of Hologic products. There can be no guarantee that these products will provide the benefits described herein or that these benefits will be replicated in any particular way with respect to an individual patient, as the actual effect of using the products can only be determined. ‘case by case. – case by case. Further, there can be no assurance that such products will be commercially successful or achieve the expected level of sales. Hologic expressly disclaims any obligation or undertaking to post any updates or revisions to any of the statements set forth herein to reflect any change in expectations or any change in events, conditions or circumstances on which such data or statements are based.

This information is not intended to be a solicitation or promotion of products where such activities are prohibited. For specific information about products available for sale in a particular country, please contact a local Hologic sales representative or write to [email protected]

____________________

1

Publication for reference: Kaur, Piccolo, Arasaratnam. Implementation of Contrast Mammography in Clinical Practice, Chapter 7, Nori, Kaur (eds.), contrast-enhanced digital mammography (CEDM). Springer, 2018.

2

Hobbs MM, Taylor DB, Buzynski S and Peake RE. Contrast spectral mammography (CESM) and contrast MRI (CEMRI): patient preferences and tolerance. Journal of Medical Imaging and Radiation Oncology. 2015;59:300-305

3

Hologic Clinical Study CSR-00266 Rev 001 2022

Source: Hologic, Inc.

Leave a Comment

Your email address will not be published. Required fields are marked *

%d bloggers like this: